KNSAHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc hold a median 12-month price target of $99 — +10.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kiniksa Pharmaceuticals International Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Issuance (51): The company has been issuing shares or taking on financing, diluting existing holders.
Size (19): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on KNSA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.4% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Goldman Sachs | Maintains | Buy | $75 → $90 |
| 29 July 2026 | Canaccord Genuity | Maintains | Buy | $64 → $98 |
| 29 July 2026 | Citigroup | Maintains | Buy | $60 → $100 |
| 29 July 2026 | JP Morgan | Maintains | Overweight | $72 → $107 |
| 29 July 2026 | Wedbush | Maintains | Outperform | $72 → $99 |
| 23 July 2026 | Goldman Sachs | Maintains | Buy | $60 → $75 |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | $57 → $74 |
| 29 June 2026 | Wedbush | Maintains | Outperform | — |
| 29 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 29 Apr 2026 | Citigroup | Maintains | Buy | — |
| 29 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 29 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 28 Apr 2026 | Jefferies | Maintains | Buy | — |
| 16 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 25 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 25 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 19 Feb 2026 | Canaccord Genuity | Initiates | Buy | — |
| 13 Jan 2026 | Wedbush | Maintains | Outperform | — |
| 29 Oct 2025 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KNSA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Kiniksa Pharmaceuticals International Plc returned +119.7% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 18% of US stocks
Cheaper than 10% of US stocks
Cheaper than 5% of US stocks
Higher than 87% of US stocks
Higher than 72% of US stocks
Higher than 67% of US stocks
Higher than 66% of US stocks
Higher than 69% of US stocks
Higher than 72% of US stocks
Higher than 88% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kiniksa Pharmaceuticals International Plc has a market value of $5.6B and an enterprise value of $5.2B.
Revenue in the twelve months to 30 June 2026: $840.8M. The latest quarter grew 55.4% year on year.
Net income over the same four quarters: $80.7M, a 9.6% net margin.
Diluted earnings per share, trailing twelve months: $0.97.
Free cash flow in the twelve months to 30 June 2026: $182.8M.
Kiniksa Pharmaceuticals International Plc spent $11.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 73.7×; forward P/E: 44.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Kiniksa Pharmaceuticals International Plc employs 366 people — $2.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kiniksa Pharmaceuticals International Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kiniksa raised its 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among patients with multiple recurrences reached 23%.
Why it matters — The updated revenue guidance and ARCALYST penetration are key operating developments for KNSA watchers.
Kiniksa raised its full-year 2026 revenue guidance after reporting 58% year-over-year growth in third-quarter ARCALYST revenue. The company also cited continued expansion of the drug's use for recurrent pericarditis and progress in its clinical pipeline.
Why it matters — The update provides KNSA watchers with information on ARCALYST's recent revenue growth, expanded use, and the company's outlook and pipeline progress.
Seeking Alpha published a transcript of Kiniksa Pharmaceuticals International, plc’s Q3 2026 earnings call. The provided excerpt contains no further details about the call.
Why it matters — The transcript may provide KNSA watchers with management’s discussion, but the excerpt itself does not include specific company updates.
Kiniksa Pharmaceuticals reported quarterly earnings of $0.56 per share, above the Zacks Consensus Estimate of $0.32. Earnings were $0.23 per share in the year-ago quarter.
Why it matters — KNSA watchers may note that quarterly earnings exceeded the consensus estimate and were higher than a year earlier.
Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0 million, up approximately 58% year over year, and raised its expected 2026 net product revenue range to $1.045–$1.050 billion. It also said pivotal Phase 3 data for KPL-387 are expected in the second half of 2027.
Why it matters — The update gives KNSA watchers information on ARCALYST’s reported sales growth and the company’s revised 2026 revenue expectation, as well as a timeline for KPL-387’s pivotal data.
The 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc have a median 12-month price target of $99, with estimates ranging from $87 to $108. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Kiniksa Pharmaceuticals International Plc, 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Kiniksa Pharmaceuticals International Plc ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +10.4% from the last close, and Ticker Nerd's factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kiniksa Pharmaceuticals International Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KNSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $87 to $108 over the next 12 months.
Kiniksa Pharmaceuticals International Plc returned +119.7% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation.
The most recent item we track (The Motley Fool, 27 Oct 2026): "Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors". Kiniksa raised its 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among patients with multiple recurrences reached 23%.
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation. Kiniksa serves patients and healthcare providers in the United States, the United Kingdom, and other international markets, with emphasis on specialized treatments for cardiovascular and autoimmune disorders. The company’s role in the healthcare sector is defined by its concentration on targeted biologic medicines that address serious conditions with limited treatment options. Headquartered in London, Kiniksa Pharmaceuticals International, plc operates as a commercial-stage biopharmaceutical business within the global specialty drug market.
CEO Mr. Sanjiv K. Patel · 366 employees · United Kingdom · https://www.kiniksa.com
